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Kyoto, Japan 
The effect of prednisolone on viral myocarditis was stud•
ied in BALB/c mice with encephalomyocarditis virus myo•
carditis. Prednisolone was injected intramuscularly, 10 
mg/kg once a day, on days 4 to 13 (experiment 1) and 
on days 8 to 17 (experiment 2). The control mice in each 
experiment received injections of distilled water. 
In experiment 1, myocardial virus titers were max•
imal but neutralizing antibodies were rarely present on 
day 4, and viral titers were still elevated and antibody 
titers were high on day 8. The survival rate of the pred•
nisolone group was significantly lower (p < 0.05) than 
that of the control group on days 21, 22 and 23. On day 
10, the antibody titers of the prednisolone group were 
significantly lower (p < 0.01) than those of the control 
The use of corticosteroids for the treatment of acute viral 
myocarditis has been controversial. Kilbourne et al. (1) 
reported that a single injection of cortisone in an early stage 
of infection with Coxsackie B3 virus increased both the 
severity of myocardial damage and the incidence of lethal 
disease in mice. The results of their experimental study led 
numerous investigators (2-9) to denounce the use of steroids 
in the early stage of the disease. Nonetheless, there were 
many clinical reports of the successful use of these agents 
(10-12). However, the influence of steroids on the different 
stages of viral myocarditis in an experimental model has 
not been studied, nor have the clinical studies been controlled. 
We have shown that the myocardiotrophic variant of 
encephalomyocarditis virus produced extensive myocarditis 
and congestive heart failure in BALB/c mice in the acute 
stage (13) and caused cardiac lesions similar to those seen 
in some patients with dilated (congestive) cardiomyopathy 
in DBAl2 mice in the chronic stage (14). We have also 
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group, and viral titers of the prednisolone group re•
mained significantly elevated (p < 0.01), whereas viruses 
were rarely isolated in the control group. In experiment 
2, the survival rate and antibody titers were not signif•
icantly different in the prednisolone and control groups. 
In both experiments, no viruses were isolated on day 14. 
The present study suggests that corticosteroids given 
in the early stage aggravate the course of acute viral 
myocarditis, and that they may not have detrimental 
effects if given when neutralizing antibody titer levels 
are high, although they are not expected to have a ben•
eficial effect. 
(J Am Coli CardioI1986;7:868-72) 
demonstrated the serial electrocardiographic changes (15) 
and immunologic behavior of lymphocytes (16) in the DBAl2 
mice with myocarditis. The present experiment was de•
signed to evaluate the effects of prednisolone on acute viral 
myocarditis due to encephalomyocarditis virus in mice. 
Methods 
Experimental infection and prednisolone treat•
ment. BALB/c mice. 4 to 5 weeks old, were inoculated 
intraperitoneally with 0.1 ml of the myocardiotrophic var•
iant of encephalomyocarditis virus suspension containing 
102.5TCD5o (50% tissue culture infective dose). Predniso•
lone was administered intramuscularly, 10 mg/kg once a 
day, on days 4 to 13 (experiment 1) and on days 8 to 17 
(experiment 2). The control mice in each experiment were 
given intramuscular injections of 0.1 ml of distilled water. 
The mice were observed for 10 days after the last admin•
istration, and survival rate was determined in each experi•
ment (20 mice in each group in experiment 1 and 36 mice 
in each group in experiment 2). In experiment 2, some mice 
continued to be observed to 60 days after the inoculation. 
To compare myocardial virus titers, neutralizing antibody 
titers and histologic findings, five mice in each group were 
killed by exsanguination as follows: in experiment 1, on 
days 4, 8, 10 and 14 in the control group and on days 8, 
0735-1097/86/$3.5,0 
JACC VoL 7, No 4 
Apnl 1986.868-72 
to and 14 in the prednisolone group; in experiment 2, on 
day 14 in both groups. The hearts were sectioned trans•
versely at the midportion of the ventricle aseptically and 
processed for virus titrations and histologic examination. In 
experiment 1, viral titers in the brains and histologic findings 
of brains were examined. 
Virus titrations. The hearts and brains were ground with 
sea sand, and 1 and 10% suspensions, respectively, in Ea•
gle's minimum essential medium were made up. After cen•
trifugation, the supernatants were taken as 10-fold dilutions 
in the titration and O. 1 ml of each sample was inoculated 
into tube cultures of human amnion cells containing 1.0 ml 
of the minimum essential medium supplemented with 2% 
fetal calf serum. Virus was quantitated by determining the 
TCDsoig of tissue. 
Neutralizing antibody titrations. Blood was obtained 
under sterile conditions from the retroorbital plexus, and 
the serum was inactivated (56°C for 30 minutes). Each sam•
ple was titrated serially by determining the final twofold 
dilution in 1.0 ml of the minimum essential medium sup•
plemented with 2% fetal calf serum that protected human 
amnion cell monolayers against a challenge of 100 TCDso 
virus. Antibody titers were expressed as the highest serum 
dilution that neutralized 50% of the viral inoculum. 
Histologic examination. The hearts and brains were fixed 
in 10% formalin and stained with hematoxylin-eosin. The 
extent of myocardial necrosis and inflammation was graded 
blindly. Necrosis was scored from 0 to 4: grade 0 indicated 
no lesions or questionable lesions; grade 1 indicated that 
less than 25% of the sampled myocardium contained lesions; 
grades 2, 3 and 4 indicated 25% increments. Inflammation 
was scored as 1, 2 and 3, respectively, for mild, moderate 
and extensive infiltration of inflammatory cells in the ne•
crotic lesions. 
Statistical analysis. Student's t test or the Mann-Whit•
ney U test was used to evaluate differences in the viral titers 
in the organs, neutralizing antibody titers and necrosis and 
inflammation scores. Fisher's exact test was used to deter•
mine the significance of differences in the mortality rate. 
The average titers of neutralizing antibody were expressed 
as mean ± SD U/ml. 
Results 
Experiment 1. Survival rate. Each group in experiment 
1 comprised 20 mice. Eleven mice in the prednisolone group 
and nine in the control group died during the treatment 
period, that is, by day 13. After treatment, 6 of 9 surviving 
mice in the prednisolone group died, whereas only 1 of 11 
control mice died. Therefore, the survival rate of the pred•
nisolone group was significantly lower (p < 0.05) than that 
of the control group on days 21 to 23 (Fig. 1). 
Myocardial virus titers. Viral titers were maximal on 
day 4 in the control group before injection. In the predni-
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Figure 1. Survival rate in experiment 1. The survival rate of the 
prednisolone group was significantly (p < 0.05) lower than that 
of the control group on days 21 to 23. 
solone group, viral titers were almost the same as those of 
the control group on day 8, but remained significantly el•
evated (p < 0.01) on day to, at which time only one of 
five control mice had a demonstrable viral titer, and this 
was low. Viruses were not isolated on day 14 in either group 
(Fig. 2). 
Viral titers in the brains. Maximal levels of virus were 
present on day 4 in the control group before injection (Table 
1). Viral titers slowly dropped thereafter in both groups. 
Viruses were not isolated on day 14 in either group. 
Neutralizing antibody titers. In the control group, almost 
no neutralizing antibodies could be detected on day 4. On 
day 8 the average titer was 241 ± 160 U/ml. Titers on days 
to and 14 were 251 ± 152 and 443 ± 181 U/ml, respec•
tively. The average titers of the prednisolone group on days 
Figure 2. Comparison of myocardial virus titers between the pred•
nisolone and control groups in experiment 1. Each point represents 
one mouse. In the prednisolone group viral titers remained sig•
nificantly elevated on day 10, whereas only one of five control 
mice had a demonstrable viral titer. TCDso = 50% tissue culture 
infective dose. 
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Table 1. Virus Titration in the Brain in Experiment I 
Viral Titers* 
p 
Days Control Group Prednisolone Group Value 
4 7.1 ± 0.8 (4/4)t 
8 4.9 ± 0.5 (4/4) 5.5 ± 0.7 (4/4) NS 
\0 3.3 ± 0.3 (3/4) 2.8 ± 0.8 (3/4) NS 
14 ND ND 
*Mean LoglOTCDsoig ± SD. tNumber of mice with ViruS isola•
tion/number examined. ND = not detected; NS = not significant; TCD 
= tissue culture infective dose. 
8 and 10 were 50 ± 14 and 87 ± 26 Vlml, respectively. 
They were significantly lower than those of the control group 
(p < 0.01 for both). However, they increased to the same 
levels (627 ± 257 VIm!) as those of the control group on 
day 14 (Fig. 3). 
Experiment 2. Survival rate. Each group in experiment 
2 comprised 36 mice. The survival rate of the prednisolone 
group on day 27 was the same as that of the control group 
(Fig. 4). Six mice in both groups continued to be observed 
to day 60 and the others were killed to examine the histologic 
findings. 
Myocardial virus titers. No viruses were isolated on day 
14 in either group. 
Neutralizing antibody titers. On day 14, the average titer 
was 401 ± 110 Vlml in the prednisolone group and 313 
± 128 Vlml in the control group. The difference was not 
significant (Fig. 5). 
Histologic examination. Myocardial lesions were exten•
sive in the right and left ventricles and in the interventricular 
septum in both groups. Mice dying after day 12 showed 
Figure 3. Comparison of neutralizing antibody titers between the 
prednisolone and control groups in experiment I. Each point rep•
resents one mouse. The antibody titers of the prednisolone group 
on days 8 and 10 were significantly lower than those of the control 
group (p < 0.01 for both). 
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Figure 4. Survival rate in experiment 2. The survival rate was 
not different in the two groups. 
pleural effusion and ascites; thus, the cause of death seemed 
to be congestive heart failure. 
The scores of necrosis and inflammation in the acute 
stage are summarized in Table 2. The extent of necrosis on 
day 14 was slightly greater in the prednisolone group than 
in the control group in both experiments. However, no sig•
nificant differences in the scores of myocardial necrosis and 
cellular infiltration were noted between the prednisolone and 
control groups on days 8, 10 and 14 in both experiments. 
In experiment 2, on days 27 and 60, cellular infiltrations 
gradually decreased and interstitial fibrosis increased. There 
was no qualitative difference in the type of myocardial le•
sions between the two groups at this stage. 
Brain lesions were never extensive nor were they found 
regularly in both groups. Necrosis of nerve cells, focal ne•
crosis with small round cell infiltrations and occasionally 
extensive cell infiltrations in the meninges were seen. 
Figure S. Comparison of neutralizing antibody titers between the 
prednisolone and control groups in experiment 2. Each point rep•
resents one mouse. Open circles on day 8 indicate the control 
mice in experiment 1. On day 14, the average titer was not sig•
nificantly different in the two groups. 
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Table 2. Scores of Myocardial Histologic Lesions in Experiments 1 and 2 
Necrosis Inflammation 
Days After Control Group Prednisolone Group Control Group Prednisolone Group 
Expenment Inoculation (n = 5) (n = 5) (n = 5) (n = 5) 
8 1 2233 22333 23333 23333 
I 10 I 2333 23333 33333 1 2333 
I 14 I I I 23 I 2333 1 2223 12222 
2 14 12223 22333 23333 22233 
Discussion 
In this study, administration of prednisolone at a time 
when neutralizing antibodies were barely detected impaired 
the viral clearance from the hearts and decreased the survival 
rate. However, when neutralizing antibody levels were high, 
prednisolone neither enhanced viral dissemination nor low•
ered the survival rate. Histologically, a chronic toxic effect 
of prednisolone on the myocardium was not observed. Al•
though prednisolone did not improve the survival rate, in 
this stage of the disease it is unlikely that steroids might 
have detrimental effects, as has been stressed before (1). 
Viruses were recovered from the brain and myocardium 
of mice infected with the myocardiotrophic variant of en•
cephalomyocarditis virus. There was no significant differ•
ence between the control and the prednisolone group in the 
viral titers of the brain. On histologic examination, focal 
necrosis and meningitis were found. This finding suggests 
that encephalomeningitis may be related to the cause of 
death in the early stage. However, mice dying after day 12 
had pleural effusion or ascites, whereas mice exhibited pa•
resis of the limbs sporadically. The cause of death at this 
stage seemed to be congestive heart failure. 
Role of neutralizing antibody in viral clear•
ance. Encephalomyocarditis virus is a picornavirus biolog•
ically similar to the Coxsackie virus, which is a cytopathic 
virus and the most commonly identified cause of viral heart 
disease in humans. Host defense mechanisms in acute cy•
tolytic infections most likely depend on a balance between 
viral clearance by macrophages and neutralizing antibody 
and cell mediated lysis of infected cells by NK cells, an•
tibody-dependent cells and cytotoxic T lymphocytes. Many 
of these defense mechanisms seem to be overlapping (17). 
and steroids have many effects on macrophages and lym•
phocytes (18), so that it is difficult to identify a single 
property of steroids that is responsible for their immuno•
suppressive activity. 
It is suggested that neutralizing antibody and macro•
phages collaborate to limit viral replication and terminate 
active infection (19). The importance of neutralizing anti•
body in eliminating virus was demonstrated by experiments 
with passive immunization against infection by Coxsackie 
B3 virus (20) and encephalomyocarditis virus (21). In this 
study, mice in experiment 1 receiving prednisolone mani•
fested inhibition of the neutralizing antibody synthesis with 
higher viral titers in the myocardium compared with the 
control group. The exacerbating effect of prednisolone may 
be related in part to its ability to inhibit synthesis of neu•
tralizing antibody. The present study also demonstrated that 
the effect of prednisolone on neutralizing antibody synthesis 
depended on the time of administration. 
Effects of steroids in clinical studies. The efficacy of 
steroids in the treatment of acute viral myocarditis has been 
controversial, both in experimental and in clinical studies 
(1-12). After Mason et al. (22) reported that endomyocar•
dial biopsy could be used to monitor the results of therapy 
histologically and that immunosuppressive therapy that in•
cluded prednisone was effective in some patients with 
congestive heart failure due to acute myocarditis, many trials 
of immunosuppressive therapy followed by endomyocardial 
biopsy were reported (23-25). Fenoglio et al. (25) classified 
myocarditis into three groups according to histologic ap•
pearance on endomyocardial biopsy: acute, rapidly pro•
gressive and chronic myocarditis. They evaluated the re•
spective responses to immunosuppressive therapy and showed 
that there was no improvement in cardiovascular function 
in acute and rapidly progressive myocarditis, in contrast to 
chronic myocarditis. However, the inflammatory infiltration 
was diminished in repeat biopsies in all cases. Therefore, 
they postulated that immunosuppressive therapy did not ag•
gravate the disease in any patient. 
Clinical implications. The present experiment in mice 
suggests that steroids may aggravate the course of acute 
viral myocarditis if administered when neutralizing antibody 
titers are scarce and that steroids may not have detrimental 
effects if given when neutralizing antibody titer levels are 
high, although a beneficial effect of steroids is not expected. 
Extrapolation of the results of this study to humans should 
be done with caution. because there are remarkable differ•
ences in susceptibility to steroids between mice (a steroid•
sensitive species) and humans (a steroid-resistant species) 
(26) and because various viruses other than enteroviruses 
may cause myocarditis (9). The effects of steroids on acute 
viral myocarditis in steroid-resistant animals such as the 
monkey and guinea pig, and on viral myocarditis due to 
other cardiotropic viruses should be studied. 
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